Lu177PSMAterapi

Lu177PSMAterapi, also known as Lutetium-177 PSMA therapy, is a targeted radioligand therapy used primarily in the treatment of prostate cancer that has spread (metastasized) to other parts of the body. The treatment combines a radioactive isotope of lutetium (Lu-177) with a molecule called PSMA (prostate-specific membrane antigen), which is highly expressed on the surface of prostate cancer cells. This approach allows the radiation to be delivered directly to cancerous tissues while sparing healthy cells.

Developed in recent years, Lu177PSMAterapi has shown promising results in clinical trials, particularly for patients with castration-resistant prostate cancer (CRPC) that has progressed despite other treatments. The therapy is administered intravenously, typically in multiple cycles, with each cycle involving a few hours of infusion followed by a period of monitoring for side effects. The radiation emitted by Lu-177 targets and damages the DNA of cancer cells, slowing or halting their growth.

Common side effects of Lu177PSMAterapi may include fatigue, nausea, dry mouth, and mild bone pain, though these are generally manageable. More serious side effects, such as kidney or bone marrow toxicity, are rare but require careful monitoring. Patients undergoing this treatment often undergo hydration therapy and kidney protection measures, such as the administration of amino acids, to mitigate potential risks.

Lu177PSMAterapi is not a cure for prostate cancer but is intended to prolong survival and improve quality of life for patients with advanced disease. Its use is typically reserved for those who have exhausted other standard treatments, such as hormone therapy and chemotherapy. The therapy is not suitable for patients with early-stage prostate cancer or those with widespread bone metastases that cause severe pain or spinal cord compression.

Clinical guidelines and regulatory approvals for Lu177PSMAterapi vary by country. In Europe, it has been approved under the name Pluvicto (177Lu-PSMA-617) for patients with PSMA-positive metastatic CRPC who have received prior androgen receptor pathway inhibition and taxane-based chemotherapy. Ongoing research continues to explore its efficacy in different patient populations and potential combinations with other therapies.